Diagnostics, therapeutics and RET inhibitor resistance for RET fusion-positive non-small cell lung cancers and future perspectives.

MLA

Lu, Chang, and Qing Zhou. “Diagnostics, Therapeutics and RET Inhibitor Resistance for RET Fusion-Positive Non-Small Cell Lung Cancers and Future Perspectives.” Cancer Treatment Reviews, vol. 96, May 2021, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.ctrv.2021.102153.

APA

Lu, C., & Zhou, Q. (2021). Diagnostics, therapeutics and RET inhibitor resistance for RET fusion-positive non-small cell lung cancers and future perspectives. Cancer Treatment Reviews, 96, N.PAG. https://doi.org/10.1016/j.ctrv.2021.102153

Chicago

Lu, Chang, and Qing Zhou. 2021. “Diagnostics, Therapeutics and RET Inhibitor Resistance for RET Fusion-Positive Non-Small Cell Lung Cancers and Future Perspectives.” Cancer Treatment Reviews 96 (May): N.PAG. doi:10.1016/j.ctrv.2021.102153.